Curasight (CURAS) Q1 2026 earnings summary

Executive summary

• Advanced uPAR-targeted theranostic platform with progress in both UTREAT® therapy and UTRACE® diagnostics during Q1 2026, including encouraging preliminary Phase 1 data in high-grade gliomas.

• Strengthened Board with two international healthcare leaders, enhancing expertise in radioligand therapy and commercialization.

• Increased visibility through participation in major healthcare conferences and strategic investor engagement.

• Completed partial conversion of convertible loan, reducing debt and broadening long-term shareholder base.

Financial highlights

• Gross loss for Q1 2026 was KDKK -13,078, compared to KDKK -4,699 in Q1 2025.

• Operating loss amounted to KDKK -15,278 (Q1 2025: KDKK -6,209); loss before tax was KDKK -16,704 (Q1 2025: KDKK -6,579).

• Loss for the period was KDKK -15,329, up from KDKK -5,204 year-over-year.

• Cash at March 31, 2026, was KDKK 22,088, compared to KDKK 1,514 a year earlier.

• Equity ratio improved to 19.0% from 14.2% year-over-year.

• Earnings per share was DKK -0.32 (Q1 2025: DKK -0.25).

Outlook and guidance

• Focus remains on advancing clinical development of UTREAT® and UTRACE®, with key milestones expected in 2026, including additional clinical data and patient enrollment.

• Anticipates increased strategic and commercial interest in radiopharmaceuticals, leveraging recent industry momentum.